 WATERTOWN, Mass., Dec. 07, 2020 GLOBE NEWSWIRE -- Kymera Therapeutics, Inc. NASDAQ: KYMR, a biopharmaceutical company advancing targeted protein degradation to deliver novel, small molecule protein degrader therapeutics, today announced the company presented preclinical data that further support development of its highly selective and potent IRAKIMiD and STAT3 protein degraders scheduled to enter the clinic in 2021. Data were presented at the virtual 62nd American Society of Hematology ASH Annual Meeting, Dec. 5-8, 2020 in three separate poster presentations. 